Chester County News and Community Website
MALVERN, PA — MAXONA Pharmaceuticals has officially emerged from stealth mode, announcing the successful completion of its U.S. Phase 1 clinical trials for MAX-001, a groundbreaking non-opioid, non-NSAID oral therapy designed …
MAXONA Pharmaceuticals Completes Phase 1 Trials for Breakthrough Pain Therapy Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the expansion of SELVA, its Phase 3 clinical trial of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), to include children as young …
Palvella Therapeutics Expands Phase 3 Trial to Younger Patients Read More
KING OF PRUSSIA, PA — CSL (ASX: CSL; USOTC: CSLLY) has unveiled four-year results from its pivotal HOPE-B study, demonstrating the long-term durability and safety of HEMGENIX® (etranacogene dezaparvovec-drlb), the …
CSL Reports Promising Four-Year Data on Gene Therapy for Hemophilia B Read More
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has initiated its pivotal Phase 3 clinical trial evaluating buntanetap as a treatment for early Alzheimer’s disease (AD), marking an important step forward …
Annovis Bio Launches Phase 3 Trial for Alzheimer’s Drug Buntanetap Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced the completion of enrollment for its Explore-CKD Phase 2 trial. The study is evaluating the efficacy and safety of lorundrostat, …
Mineralys Therapeutics Completes Enrollment for Explore-CKD Phase 2 Trial Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has reached a significant milestone in the development of its gene-agnostic therapy, OCU400, as the European Commission has delivered a positive opinion designating it …
Ocugen’s OCU400 Receives ATMP Classification from European Commission, Advancing Retinitis Pigmentosa Treatment Read More
PHILADELPHIA, PA — Imvax, Inc, recently closed a $29 million financing round from existing investors. This marks the latest milestone in the company’s fundraising efforts, which have totaled $86 million …
Imvax Secures $29 Million to Advance Glioblastoma Therapy Trial Read More MALVERN, PA — Biopharmaceutical company Ocugen, Inc. (NASDAQ: OCGN) has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for OCU500, a novel …
Ocugen Receives FDA Greenlight for Phase 1 Trial of Mucosal COVID-19 Vaccine Read More
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) has announced promising results from its pivotal Phase 3 Vivacity-MG3 study evaluating nipocalimab, an investigational FcRn blocker, for generalized myasthenia gravis (gMG). …
Johnson & Johnson Reports Landmark Phase 3 Study Results for gMG Treatment Read More
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has announced the successful completion of Phase I clinical trials for tivoxavir marboxil, an investigational one-dose treatment aimed at combating H5N1 bird flu. …
Traws Pharma Advances Bird Flu Treatment with Successful Phase I Trial Read More